August 2015, Vol 4, No 4
Showcasing the Success of Precision Medicine
In this issue of Personalized Medicine in Oncology (PMO), we are pleased to offer a wealth of information showcasing the success of precision medicine. Breakthroughs in screening, diagnosing, and treating patients based on the specific biology of individuals and their tumors have impacted our ability to turn some cancers from an acute disease to a chronic one and thereby extend the life of patients.
In this and subsequent issues, we highlight the proceedings from our own PMO Live Annual Meeting, which took place in Seattle, WA, July 22-25, 2015. PMO Live is a joint meeting of the Global Biomarkers Consortium and the World Cutaneous Malignancies Congress focusing on personalized medicine techniques in oncology. Expert faculty and attendees gathered at the meeting to explore the application of new diagnostics, biomarkers, and drug regimens, in addition to the rapid changes to the healthcare system and their impact on oncology care and access for patients.
In our Interview with the Innovators, you will meet Drs Dixie-Lee Esseltine and George Mulligan of the Takeda Company. They provide insights to the impact of oral oncolytics for those patients with multiple myeloma.
Also in this issue of PMO, we highlight a review from Drs Brian T. Helfand and Charles B. Brendler entitled “A Genetic-Based Approach to Individualized Prostate Cancer Screening and Treatment,” as well as important presentations from the American Society of Clinical Oncology.
Thank you so much for your loyal readership. It is a pleasure to serve you in our quest to improve the lives of patients.
Al B. Benson III, MD, FACP, FASCO
Coeditor in Chief
Personalized Medicine in Oncology
The IDH1 gene and the ATRX gene appear to be potential prognostic markers for anaplastic astrocytoma, a rare form of brain cancer, according to findings of a phase 3 trial. Patients with a mutated IDH1 gene survived for a mean of 7.9 years after diagnosis versus 2.8 years for patients [ Read More ]
Results from the phase 3 GADOLIN trial provide the first proof of efficacy for obinutuzumab in indolent non-Hodgkin lymphoma (NHL). Obinutuzumab added to standard bendamustine chemotherapy more than doubled progression-free survival (PFS) in patients with rituximab-refractory indolent lymphoma: median PFS was 29.2 months with obinutuzumab/bendamustine versus 14 months with bendamustine [ Read More ]